Developmental and Epileptic Encephalopathy

Oncology·MeSH: Seizures

Prevalence

0.5 / 100K

8 drugs in development·5 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
1.0mg/kg/day PRAX-562	Praxis Precision Medicines, Inc. (PRAX)
1.5mg/kg/day PRAX-562	Praxis Precision Medicines, Inc. (PRAX)
Bexicaserin (LP352)	Longboard Pharmaceuticals, Inc. (LBPH)
LP352	Longboard Pharmaceuticals, Inc. (LBPH)
LP352, bexicaserin	Longboard Pharmaceuticals, Inc. (LBPH)

Phase 2(2)

Drug	Company
nbi-921352	Xenon Pharmaceuticals Inc. (XENE)
nbi-921352	NEUROCRINE BIOSCIENCES INC (NBIX)

Phase 1/Phase 2(1)

Drug	Company
gene therapy	Gene Biotherapeutics, Inc. (CRXM)

BioSniper tracks 8 drugs in development for Developmental and Epileptic Encephalopathy across 5 companies.

There are 4 clinical trials targeting Developmental and Epileptic Encephalopathy tracked by BioSniper.

The estimated prevalence of Developmental and Epileptic Encephalopathy is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.